Digestive Diseases and Sciences

, Volume 60, Issue 9, pp 2813–2824 | Cite as

Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review

  • Harleen K. Dyal
  • Maria Aguilar
  • Taft Bhuket
  • Benny Liu
  • Edward W. Holt
  • Sharon Torres
  • Ramsey Cheung
  • Robert J. Wong
Original Article



Rising rates of obesity, diabetes mellitus (DM), and nonalcoholic fatty liver disease among patients with chronic hepatitis C virus infection (HCV) may contribute to more rapid disease progression.


To evaluate the impact of concurrent obesity, DM, and steatosis on disease progression among HCV patients.


A systematic review using structured keyword search of MEDLINE and EMBASE from January 1, 2001, to July 1, 2014, was performed to identify original articles evaluating the association of obesity, DM, and steatosis with advanced fibrosis (AF) among adults with chronic HCV. Studies involving HCV patients coinfected with human immunodeficiency virus, hepatitis B virus, hepatocellular carcinoma, or other chronic liver diseases were excluded. Quality assessment utilized Newcastle–Ottawa Scale.


Twenty cohort studies met inclusion criteria for analyses. Obesity was associated with increased risk of AF in seven studies with effect size ranging from OR 1.08 to 7.69. However, four studies did not demonstrate a significant association between obesity and AF. The presence of advanced steatosis among HCV patients was associated with increased risk of AF in 12 studies (OR 1.80–14.3). Concurrent DM was associated with increased risk of AF in six studies (OR 2.25–9.24). Thirteen studies were good quality, and seven studies were fair quality.


Concurrent DM and steatosis are associated with increased risk of AF among chronic HCV patients. The majority of studies demonstrated significant associations of obesity with AF. Targeted interventions to optimize management of obesity-related diseases among HCV patients may help mitigate HCV disease progression.


Body mass index Metabolic syndrome Nonalcoholic steatohepatitis Fibrosis 


Conflict of interest

The authors of this manuscript have no conflicts of interest to disclose as described by Digestive Diseases and Sciences.

Supplementary material

10620_2015_3760_MOESM1_ESM.docx (29 kb)
Supplementary material 1 (DOCX 28 kb)


  1. 1.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567.CrossRefPubMedGoogle Scholar
  2. 2.
    Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.CrossRefPubMedGoogle Scholar
  3. 3.
    Hu SX, Kyulo NL, Xia VW, et al. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of US patients. J Clin Gastroenterol. 2009;43:758–764.CrossRefPubMedGoogle Scholar
  4. 4.
    Everhart JE, Lok AS, Kim HY, HALT-C Trial Group, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137:549–557.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705–709.CrossRefPubMedGoogle Scholar
  6. 6.
    El Ray A, Asselah T, Moucari R, et al. Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C. Eur J Gastroenterol Hepatol. 2013;25:421–427.PubMedGoogle Scholar
  7. 7.
    Petta S, Cammà C, Di Marco V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int. 2011;31:507–515.CrossRefPubMedGoogle Scholar
  8. 8.
    Verma S, Bonacini M, Govindarajan S, et al. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol. 2006;101:1817–1823.CrossRefPubMedGoogle Scholar
  9. 9.
    Huang YW, Yang SS, Fu SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology. 2014;60:807–814.CrossRefPubMedGoogle Scholar
  10. 10.
    Nieminen U, Arkkila PE, Kärkkäinen P, et al. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. Liver Int. 2009;29:153–158.CrossRefPubMedGoogle Scholar
  11. 11.
    Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002;97:2408–2414.CrossRefPubMedGoogle Scholar
  12. 12.
    Patel K, Thompson AJ, Chuang WL, et al. Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. J Gastroenterol Hepatol. 2011;26:1182–1188.CrossRefPubMedGoogle Scholar
  13. 13.
    Alsatie M, Kwo PY, Gingerich JR, et al. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2007;41:416–421.CrossRefPubMedGoogle Scholar
  14. 14.
    Cross TJ, Quaglia A, Hughes S, et al. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16:492–499.CrossRefPubMedGoogle Scholar
  15. 15.
    Castéra L, Hézode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52:288–292.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;5:1181–1191.CrossRefGoogle Scholar
  17. 17.
    Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147–154.CrossRefPubMedGoogle Scholar
  18. 18.
    Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54:1003–1008.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut. 2009;58:1662–1669.CrossRefPubMedGoogle Scholar
  20. 20.
    Muzzi A, Leandro G, Rubbia-Brandt L, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol. 2005;42:41–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004;53:406–412.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Ong JP, Younossi ZM, Speer C, et al. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266–271.CrossRefPubMedGoogle Scholar
  23. 23.
    Petta S, Cammà C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103:1136–1144.CrossRefPubMedGoogle Scholar
  24. 24.
    Bhat G, Baba CS, Pandey A, et al. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop Gastroenterol. 2013;34:18–24.CrossRefPubMedGoogle Scholar
  25. 25.
    Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28:11–17.CrossRefPubMedGoogle Scholar
  26. 26.
    Hassan K, Bhalla V, El Regal ME, et al. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082–12101.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Wong RJ, Chou C, Sinha SR, et al. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437–445.CrossRefPubMedGoogle Scholar
  28. 28.
    Wiese M, Fischer J, Löbermann M, East German HCV Study Group, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Shah SR, Patel K, Marcellin P, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol. 2011;9:688–693.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403–2412.CrossRefPubMedGoogle Scholar
  31. 31.
    Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18:e516–e522.CrossRefPubMedGoogle Scholar
  32. 32.
    Khan A, Tanaka Y, Azam Z, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol. 2009;81:1189–1197.CrossRefPubMedGoogle Scholar
  33. 33.
    Lonardo A, Adinolfi LE, Restivo L, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 2014;20:7089–7103.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528–540.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Jha DK, Mittal A, Gupta SP, et al. Association of type II diabetes mellitus with hepatocellular carcinoma occurrence—a case control study from Kathmandu Valley. Asian Pac J Cancer Prev. 2012;13:5097–5099.CrossRefPubMedGoogle Scholar
  36. 36.
    Memon MS, Arain ZI, Naz F, et al. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study. J Diabetes Res. 2013;2013:539361.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Harleen K. Dyal
    • 1
  • Maria Aguilar
    • 1
  • Taft Bhuket
    • 1
  • Benny Liu
    • 1
  • Edward W. Holt
    • 2
  • Sharon Torres
    • 1
  • Ramsey Cheung
    • 3
    • 4
  • Robert J. Wong
    • 1
    • 5
  1. 1.Division of Gastroenterology and Hepatology, Highland HospitalAlameda Health System – Highland Hospital CampusOaklandUSA
  2. 2.Division of Hepatology, Department of TransplantationCalifornia Pacific Medical CenterSan FranciscoUSA
  3. 3.Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA
  4. 4.Division of Gastroenterology and HepatologyVeterans Affairs Palo Alto Health Care SystemPalo AltoUSA
  5. 5.University of California, San FranciscoSan FranciscoUSA

Personalised recommendations